Business Wire

CA-TULA-TECHNOLOGY

10.11.2021 10:02:08 CET | Business Wire | Press release

Share
Tula Accelerating Innovation for a Cleaner, Greener Future

As world leaders gather in Glasgow for the 26th United Nations Climate Change Conference of the Parties (COP26), there is once again a push for strategies to reach net zero by 2050. With the transportation sector currently the fastest growing contributor to climate change and now accounting for almost a quarter of emissions, Tula Technology, Inc., a leader in propulsion efficiency, has accelerated the pace of innovation to reduce the environmental impact of passenger and commercial vehicles through its Dynamic Skip Fire (DSF®) and Dynamic Motor Drive (DMD™) technologies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110005156/en/

“To reach net zero, OEMs are faced with meeting increasingly stringent emissions reductions standards,” said R. Scott Bailey, president and CEO of Tula Technology. “Tula has developed technologies that make it possible to achieve these mandates in a cost-effective manner. Whether we’re working with partners to reduce emissions in internal combustion engines or offering solutions to make electric vehicles more efficient, our team is committed to improving propulsion efficiency for a cleaner environment.”

The Tula Track Record of Innovation

  • Using patented algorithms, DSF® chooses to skip or fire individual cylinders dynamically to meet an engine’s torque demands, enabling near-peak engine efficiency for a cleaner-burning, more fuel-efficient vehicle.
  • DMD™ mitigates efficiency losses in electric motors while significantly reducing reliance on rare-earth materials. DMD’s application to electric vehicles (EVs) has the potential to increase range while using less energy. DMD is a cost-effective, software-driven solution. Without the need for rare earth materials , potential supply chain challenges and escalating costs can be avoided.
  • A recent study of Tula’s DSF in a Class 8 truck powered by a Cummins X15 HD engine showed a 74 percent reduction in nitrogen oxides (NOX ) and a 5 percent reduction in carbon dioxide (CO2 ) . To demonstrate DSF in action, Tula recently released a “virtual test drive” video.
  • FEV, an international engineering partner to the auto industry, joined Tula to evaluate Tula’s DSF for mild hybrid diesel vehicles and found an additional 11% of CO2 was eliminated compared to industry-leading hybrid powertrains. The CO2 reduction can be achieved at a cost of about $235 (€200) per vehicle. For manufacturers of light duty commercial vehicles, this technology offers a compelling and cost-effective solution to achieve challenging Euro 7 emission standards expected to go into effect by 2026 for all new vehicles in Europe.
  • Tula and Jacobs Vehicle Systems signed an agreement and are working together to integrate DSF and Jacobs Cylinder Deactivation technology . Independent laboratory testing has demonstrated that Jacobs CDA hardware and Tula’s DSF achieve greater emission reductions when combined.
  • Tula is partnering with Chinese vehicle equipment manufacturer E-Quality Tec, Inc. to embed DSF into E-Quality’s controller . Rapidly deploying fully integrated technology will enable medium and heavy-duty diesel vehicle manufacturers in China to aggressively target simultaneous reductions in both CO2 and NOX for CN Stage VI, China’s emission standard for heavy-duty vehicles.
  • More than 1.5 million General Motors passenger vehicles are on the road in the U.S. utilizing DSF, each one saving roughly one ton of CO2 emissions each year, using the same cost-effective technology being deployed in commercial diesel and hybrid vehicles.
  • Tula’s talented team members are on the cutting edge of automotive engineering, and recently were awarded their 200th global patent and have 378 patents issued or pending .

Tula is driven to improve efficiency across all manner of transportation and reduce emissions without sacrificing performance or comfort. We support immediate action on climate and clean air regulations to promote a sustainable future powered by innovation.

About Tula Technology, Inc.

Silicon Valley-based Tula Technology provides innovative award-winning software controls to optimize propulsion efficiency and emissions across the mobility spectrum, including gasoline-powered, diesel, alternative fuel, hybrid, and electric vehicles. Tula’s culture of innovation has resulted in breakthrough technology and a robust global patent portfolio of more than 378 patents issued and pending. Tula Technology is a privately held company backed by Sequoia Capital, Sigma Partners, Khosla Ventures, GM Ventures, BorgWarner and Franklin Templeton. More information is available at www.tulatech.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye